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Hyaluronan, a long-chain polysaccharide of > 106 Da
composed of repeating N-acetylglucosamine-D-gluc-
uronic acid disaccharides, is a multifunctional extra-
cellular matrix component with key roles in cardiac
embryogenesis, cell motility and migration in wound
healing and cancer, cartilage biomechanics, tissue
hydraulic permeability and joint function (Tammi et al.
2002). Joint hyaluronan is crucial both for cavitation
during embryogenesis (Ward et al. 1999) and for mature
joint function. The hyaluronan in the synovial fluid of a
mature joint (~3.6 mg ml_1) has two main physiological
roles. First, as long recognised, hyaluronan confers
hydrodynamic viscous lubrication. Second, and only
recently recognised, it buffers fluid loss from joints
during flexion, which raises synovial fluid pressure. The
hyaluronan acts via an osmotic, concentration
polarisation mechanism that depends on the partial
reflection of hyaluronan by the synovial lining during fluid
escape. This process prevents a joint from wringing itself
dry during a sustained flexion. Synovial fluid conservation
is also supported by hyaluronan within the synovial lining
matrix, where the presence of anchored hyaluronan causes
a high hydraulic resistance (Levick et al. 1999).
Hyaluronan is secreted into joints by B-type lining cells or
‘synoviocytes’, which are distinguished from fibroblasts by
high levels of uridine diphosphoglucose dehydrogenase,
N-acetyl-b-glucosaminidase, oxidative enzymes and a
6-fold greater production of soluble hyaluronan
(Pitsillides et al. 1993; Iwanaga et al. 2000). Two
observations indicate that the secretory process in vivo is
subject to a relatively rapid physiological regulation. First,
acute hydration and/or stretch stimulates hyaluronan
secretion into synovial interstitium over a few hours
(Price et al. 1996), as may also be the case in skin, lung and
intestine (e.g. Townsley et al. 1994). Second, joint
distension increases hyaluronan secretion into the cavity
within 4 h (Coleman et al. 1997). The physiological
significance of these secretory responses is thought to be
homeostasis, namely the preservation of high, functional
hyaluronan concentrations in the face of dilutional
influences such as increased capillary filtration into the
joint cavity.
The pathways responsible for regulating the rate of
hyaluronan secretion into joints in vivo have never been
investigated. Such evidence as exists comes from work on
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Hyaluronan (HA) is important for joint cavitation, lubrication, volume regulation and synovial
fluid drainage but little is known about the regulation of joint HA synthesis/secretion in vivo. We
investigated whether HA secretion into joints in vivo can be regulated by protein kinase C (PKC).
Secretion into the knee joint cavity of anaesthetised rabbits was measured over 6 h by washout and
chromatography. Joints received intra-articular injections of Ringer vehicle (control) or an
activator of classical PKC isoforms, phorbol-12-myristate-13-acetate (PMA), at 20–2000 ng ml_1.
The effects of PKC inhibition by bisindolylmaleimide (BIM) and protein synthesis inhibition by
cycloheximide (CX) on basal and stimulated HA secretion were also studied. The endogenous HA
mass, 181 ± 8 mg (n = 26, mean ± S.E.M.), and basal secretion rate, 4.4 ± 0.4 mg h_1, indicated a
turnover time of 41 h. Secretion rate showed a dose-dependent response to PMA (n = 30), rising
5-fold to 21.7 ± 5.0 mg h_1 (n = 5) at 2000 ng ml_1 PMA (P < 0.0001, one-way ANOVA). PMA-
induced stimulation was partially suppressed by CX (HA secretion: 5.8 ± 1.7 mg h_1, n = 8,
P < 0.01) and totally blocked by BIM (HA secretion: 3.2 ± 0.6 mg h_1, n = 9, P < 0.001). Basal HA
secretion was unaffected by CX over 6 h (4.2 ± 0.7 mg h_1, n = 8) but was reduced by 29 % by BIM
(3.1 ± 0.6 mg h_1, n = 10, P = 0.03). It is concluded that: (1) PKC can stimulate HA secretion into
joints in vivo through mechanisms involving protein synthesis de novo as well as phosphorylation;
(2) basal HA secretion is only partially PKC dependent; and (3) hyaluronan synthase turnover time
is > 6 h in vivo, which is slower than in vitro (< 2–3 h).
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cultured cell lines in vitro. Biochemical studies show that
hyaluronan is synthesised at the inner face of the plasma
membrane by a membrane-spanning 63 kDa protein,
hyaluronan synthase (HAS). A cytoplasmic loop catalyses
the alternate addition of uridine diphosphoglucose
dehydrogenase (UDP)-glucuronate and UDP-N-acetyl-
glucosamine to the internal, growing end of the
hyaluronan chain, while the opposite end is continuously
extruded into the extracellular space through a channel
formed by transmembrane domains (Weigel et al. 1997;
Itano et al. 1999; Recklies et al. 2001). The physiological
significance of this unique process is that synthesis and
secretion are intimately coupled; there is no vesicle storage
and release phase. Any increase in hyaluronan secretion
rate is a direct consequence of increased hyaluronan
synthesis by HAS.
How might HAS activity be regulated in vivo? One
mechanism operating over a period of hours could be
altered genomic transcription and synthesis of HAS de
novo, a process dependent on protein synthesis. HAS
turnover can be rapid in vitro, as indicated by a HAS half-
life of ~100 min in cultured chondrocytes (Bansal &
Mason, 1986) and 120–180 min in Swiss 3T3 fibroblasts
(Kitchen & Cysyk, 1995). A second potential regulatory
mechanism is the phosphorylation of pre-existing HAS
and/or a regulatory protein (Klewes & Prehm, 1994;
Suzuki et al. 1995). HAS may exist as a complex with other
regulatory factors (Asplund et al. 1998) but the nature of
such factors is unclear in eukaryotic cells. A phosphory-
lation step at some point along the regulatory pathway
(whether pre- or postgenomic) is indicated by the finding
that hyaluronan secretion by cultured mesothelial cells, B6
cells and fibroblasts is stimulated by growth factors (e.g.
platelet-derived growth factor) and some cytokines (e.g.
interleukin b1) (Heldin et al. 1992; Klewes & Prehm, 1994),
which activate classical and novel isoforms of protein
kinase C (PKC) via the phospholipase C-g–diacylglycerol
(DAG) pathway. Direct activation of PKC by phorbol
esters likewise stimulates hyaluronan secretion in vitro.
The phenotype and metabolic response of cultured cells
can in some instances differ substantially from cells in situ,
due to their altered cellular micro-environment. Mature
synoviocytes in situ are non-confluent cells anchored to a
complex interstitial matrix by heterogeneous receptors,
whereas cultured fibroblasts etc. are usually examined at
confluence on a mono-anchor such as fibronectin or
collagen. The aims of the present study were, therefore,
first to determine whether PKC influences hyaluronan
secretion into joints by synoviocytes of normal,
physiological phenotype in situ; and second to assess
whether de novo protein synthesis is necessary for the
stimulation of hyaluronan secretion in vivo. To this end
synovial PKC was activated using intra-articular phorbol-
12-myristate-13-acetate (PMA) in the presence and
absence of the protein synthesis inhibitor cycloheximide.
Some of the findings have been published in abstract form
(Anggiansah et al. 2001).
METHODS 
Hyaluronan secretion into the knee joint cavity was measured in a
total of 45 rabbits over 6 h in vivo, using the washout method of
Coleman et al. (1997). One knee received intra-articular injections
of active agent (PMA +/_ inhibitors) and the opposite knee
received an equal volume of vehicle or PMA without inhibitor as
appropriate. The hyaluronan recovered in the washes was
analysed by high performance gel exclusion chromatography.
Materials
Phorbol-12-myristate-13-acetate (PMA, 617 Da, Calbiochem,
Nottingham, UK) was dissolved in a 50 : 50 dimethyl sulphoxide
(DMSO)–ethanol at 1 mg ml_1 and diluted with Ringer solution
to its final concentration. Solutions of 200–2000 ng ml_1 PMA
contained 0.01–0.10 % DMSO by volume and the same
concentration of ethanol. PMA at these concentrations acts at the
DAG binding site to activate the classical Ca2+-dependent
isoforms a, bI, bII and g and the Ca2+-independent novel
isoforms d, e, h and u, but not the atypical isoforms z, l and ∏
(Castagna et al. 1982; Mellor & Parker, 1998). Bisindolyl-
maleimide I (BIM, 412 Da, Calbiochem) is a highly selective, cell-
permeable inhibitor of all of the PKC isoforms tested to date,
namely a, bI, bII, g, d, e. It competitively inhibits the ATP
binding site of the PKC catalytic domain (Toullec et al. 1991).
Cycloheximide (CX, 281 Da, Sigma, Poole, UK) is an inhibitor of
ribosomal translation that is widely used to block protein
synthesis. The Ringer solution was a commercial, sterile,
nonpyrogenic product comprising (mM): 147 Na+, 4 K+, 2 Ca2+
and 156 Cl_ (Baxter Healthcare Ltd, Thetford, UK).
Animal preparation
New Zealand white rabbits of 2.5–3.0 kg were anaesthetised by I.V.
sodium pentobarbitone (30 mg kg_1) and ethyl carbamate
(500 mg kg_1). Corneal blink reflex inhibition was maintained by
repeat doses at 30 min intervals. After tracheostomy and pump
ventilation with air at 700 ml min_1 both knee joints were placed
in 100–130 deg extension. Each cavity was cannulated lateral to
the patellar ligament by an intravenous, 20 gauge, sterile,
nonpyrogenic Medicut cannula (Sherwood Medical, Tullamore,
Ireland), secured in place by a purse-string suture. The
experiments conformed to UK 1986 animal legislation. Animals
were killed by an overdose of I.V. sodium pentobarbitone (2 ml
‘Euthatal’, Rhône Mérieux Ltd, Harlow, UK) at the end of the
experiment (~6 h).
Hyaluronan mass recovery
A 1 ml volume of Ringer solution was injected slowly into the
synovial cavity and the joint flexed and extended five times to mix
the intra-articular fluid. The fluid was then aspirated, aided by
gentle pressure over the popliteal fossa. The aspirate was stored at
_80 °C for later analysis. Washout with 1 ml fresh Ringer solution
was repeated 15 times. Hyaluronan recovery is essentially
complete by the 12th to 14th wash (Coleman et al. 1997;
confirmed here). The washout was performed on both knee joints
simultaneously by two operators.
After the 15th wash each joint received a 1 ml bolus of test
solution, namely PMA +/_ inhibitor on one side and PMA alone
or vehicle (Ringer solution with a matching concentration of
DMSO and ethanol) on the contralateral side, depending on the
C. L. Anggiansah and others632 J Physiol 550.2
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particular protocol. The joints were then left for 6 h to secrete
fresh hyaluronan. Higher drug concentrations were injected in
vivo (see later) than is customary in cell culture because small,
rapidly diffusible solutes are cleared rapidly by the synovial
microcirculation (clearance ~55 ml min_1; Poli et al. 2002). To
maintain the concentration of active agent in the face of
continuous microvascular clearance, ~0.3 ml intra-articular fluid
was aspirated every 20 min and replaced with 0.5 ml fresh
solution; trans-synovial drainage over 20 min accounted for the
volume difference. The adopted replacement interval was roughly
equal to the intra-articular half-life, namely 14–24 min for solutes
of 370–582 Da (Poli et al. 2001), so that intra-articular
concentration fell by no more than a half before replenishment.
Aspirates were saved for analysis. After 6 h each joint was washed
out with a further 15 w 1 ml Ringer solution to harvest the
hyaluronan secreted de novo.
Previous studies established that basal hyaluronan secretion rate is
independent of time over 2–4 h (Coleman et al. 1997). In the
present experiments the secretory period was extended to 6 h
because cells in vitro respond maximally to PKC over 3–6 h
(Heldin et al. 1992). Previous control studies using metabolic
blockers showed that the hyaluronan recovered in the final set of
washouts represents newly synthesised material, not pre-existing
hyaluronan that has diffused into the cavity (Coleman et al. 1997).
Sample preparation
Freeze-dried aspirates were reconstituted in 300 ml Ringer
solution and treated with papain (5.6 units at 60–65 °C for 1 h;
Sigma, UK) to prevent partial masking of the small hyaluronan
band by the shoulder of a large albumin band; interstitial albumin
diffuses into the joint from the surrounding tissues. The papain
digestion step does not alter the molecular weight of the hyaluronan
(Coleman et al. 1997). Samples were centrifuged at 7.2 g for 5 min
prior to high pressure liquid chromatography (HPLC).
Hyaluronan analysis by HPLC
The recovered hyaluronan mass was quantified using size
exclusion HPLC. The system comprised a Waters 2690 separation
module (Waters Ltd, Watford, UK) with a TosoHaas TSK G6000
PWXL 300 mm w 7.8 mm column and PWXL 40 mm w 6 mm
guard column (Anachem Ltd, Luton, UK). The Tosohaas TSK-
Gel had a nominal resolution range of 40–8000 kDa (pore size
> 100 nm, particle size 13 mm). Elution profiles were measured by
a Waters 486 programmable ultraviolet absorbance detector set at
206 nm for hyaluronan analysis. Retention times and peak heights
were analysed using Waters Millenium32 software. Injection
volume was 50–100 ml and a column flow 1 ml min_1. The eluent
was Ringer solution (composition as in ‘Materials’) at room
temperature adjusted to pH 7.4 by 1 M sodium hydroxide
solution. This was vacuum filtered through a 0.2 mm membrane
(Gelman Bioscience, Northhampton, UK).
A calibration curve was constructed for each batch of samples
using known concentrations of rooster comb sodium hyaluronate
(Sigma, Poole, UK). The molecular mass of the standard,
~2000 kDa, is close to that of endogenous rabbit hyaluronan. The
calibration curve was linear from 0.006 to 0.400 mg ml_1
(Coleman et al. 1997). A molecular size calibration curve was
constructed by measuring the retention times of hyaluronan
standards of mean molecular mass 210–5500 kDa donated by Dr O.
Wik (New Pharmacia, Uppsala, Sweden). The standard molecular
weights had been determined by laser light scattering. Retention
times were essentially insensitive to pH over the range 7.0–7.4.
Protocols
Four sets of experiments were carried out. In the first the effect of
PMA at concentrations ranging from 20 to 2000 ng ml_1 was
explored. In the second, injections of 200 ng ml_1 PMA plus
3.3 mg ml_1 BIM were used to test whether the stimulatory effect of
PMA is mediated specifically through kinase activation. In the
third set, injections of 200 ng ml_1 PMA plus 100 mg ml_1 CX were
used to test whether the stimulatory effect of PMA depends on
protein synthesis de novo (cf. activation of pre-existing synthase).
The fourth set examined the effects of BIM and CX on basal
hyaluronan secretion rate, in order to test whether the basal
secretion of hyaluronan into the joint depends on basal PKC
activity and/or short-term protein synthesis.
Subsidiary experiments were carried out to test whether PMA
causes significant synovial inflammation. Inflammation was
assessed as increased fluid filtration into the joint and increased
permeation of plasma albumin labelled with Evans blue into the
joint cavity, as described by Poli et al. (2001, 2002). Other subsidiary
experiments tested whether the organic solvents in the vehicle,
namely DMSO and ethanol, influenced hyaluronan secretion.
Statistical analysis
Means ± S.E.M. are cited throughout. One-way ANOVA followed
by the Newman-Keuls test was used for multiple comparisons. All
distributions passed the Kolmogorov-Smirnov normality test at
P > 0.10, including those in Fig. 5. The results in the middle panel
of Fig. 5 appear to be skewed, however (KS statistic = 0.31). For
this reason the nonparametric Mann-Whitney U test was used for
unpaired groups. Significance was accepted at P ≤ 0.05.
RESULTS
Basal hyaluronan secretion rate and endogenous
hyaluronan turnover time
The hyaluronan concentration in each wash decreased
exponentially with wash number and fell below the HPLC
detection limit of 3 mg ml_1 by wash 12–14. The chromato-
gram retention time of 7.05 ± 0.01 min corresponded to
an average molecular mass for endogenous hyaluronan of
2.2–2.3 w 106 Da (95 % confidence intervals). The total
hyaluronan mass recovered per joint was 181 ± 8 mg
(n = 90 knees) and net volume recovery was 94 ± 1 % of
the injectate. The endogenous hyaluronan mass divided by
the mean hyaluronan concentration in rabbit knee
synovial fluid, 3.6 mg ml_1 (Price et al. 1996), indicated
that the native synovial fluid volume was 50 ml.
The mean hyaluronan secretion rate into the control
joints, i.e. those receiving drug-free injections, was
4.35 ± 0.37 mg h_1 (n = 26 joints), close to that in a smaller
study of basal secretion by Coleman et al. (1997), namely
4.80 ± 0.77 mg h_1 (n = 5). The basal secretion rate divided
by the mean endogenous mass gave the turnover rate
constant k, 0.0244 h_1. This is equivalent to a hyaluronan
intra-articular half-life of 28 h (ln 2/k) and a turnover time
for the endogenous hyaluronan mass of 41 h.
Effect of PMA on synovial hyaluronan secretion
Initially a set of eight paired experiments was carried out
with PMA in one joint and vehicle in the contralateral joint
Protein kinase C and hyaluronan secretion into jointsJ Physiol 550.2 633
Jo
u
rn
al
 o
f P
hy
si
ol
og
y
(Fig. 1, upper panel). The PMA concentration of
200 ng ml_1 (0.32 mM) was based on work on cultured B6
hybrid cells (Klewes & Prehm, 1994). In eight pairs of
rabbit knees the PMA raised the hyaluronan secretion rate
> 3-fold, from 3.4 ± 0.6 mg h_1 in the vehicle-treated
control joints to 10.7 ± 1.6 mg h_1 in the PMA-treated
joints (P = 0.002, paired t test). In a total of 14 joints
treated with 200 ng ml_1 PMA the mean hyaluronan
secretion rate, 10.1 ± 1.2 mg h_1, was 2.3 times the mean
basal rate, 4.35 ± 0.37 mg h_1 (n = 26; P < 0.0001, Mann-
Whitney U test) (Fig. 1, lower panel).
The HPLC retention times for the PMA-stimulated
hyaluronan, 7.24 ± 0.08 min, corresponded to 1.8–2.2w 106 Da (95 % confidence intervals), showing that PMA-
stimulated synovium continued to synthesise long HA
chains. This was in keeping with the finding that, of the
three mammalian isoforms HAS1, HAS2 and HAS3, rabbit
synovium expresses predominantly HAS2 mRNA, which
generates chains of > 2 w 106 Da (Spicer & Nguyen, 1999;
Ohno et al. 2001; Momberger et al. 2003). HAS3, which is
upregulated by pro-inflammatory cytokines, synthesises
shorter chains (0.1–1.0 w 106 Da; Itano et al. 1999;
Tanimoto et al. 2001).
Dose–response relation
To assess the dose–response relation, joints received intra-
articular injections of 1 ml vehicle (control, n = 26) or
PMA at 20 (n = 5), 100 (n = 3), 200 (n = 14), 500 (n = 3)
and 2000 ng ml_1 (n = 5). The hyaluronan secretion rate
increased as a function of PMA concentration (P < 0.0001,
one-way ANOVA), though not in a simple log–sigmoidal
manner (Fig. 2). At 20, 100 and 200 ng ml_1 PMA the
hyaluronan secretion rate concentration increased to
7.6 ± 2.4, 9.8 ± 4.2 and 10.1 ± 1.2 mg h_1, respectively. At
500 ng ml_1 PMA there was no further significant increase
in the secretion rate (8.5 ± 0.8 mg h_1) and the differences
between this value and those at 20, 100 and 200 ng ml_1
PMA were not significant (P > 0.05, Newman-Keuls
multiple comparison test). Because the shape of dose–
response curve up to 500 ng ml_1 hinted at a possible decay
above 200 ng ml_1, the study was extended to 2000 ng ml_1
PMA (3.2 mM). This caused a further, very large increase in
hyaluronan secretion rate to 21.7 ± 5.0 mg h_1, which was
more than double the stimulated rates evoked by
200–500 ng ml_1 PMA (P < 0.01, Newman-Keuls multiple
comparison test) and five times greater than the basal rate.
Given the shape of the dose–response relation in Fig. 2, it is
not possible to define an EC50. The hyaluronan
chromatography retention times at the highest secretion
rates (6.87 ± 0.01 min, n = 49 samples) were almost
identical to those of the matched endogenous hyaluronan
washouts (6.88 ± 0.01 min; n = 58; P = 0.4, Mann-
Whitney test), showing that hyaluronan of high molecular
mass was still being secreted.
Effect of BIM on PMA-stimulated hyaluronan
secretion
The effect of 200 ng ml_1 PMA (0.32 mM) in the presence
of the PKC inhibitor BIM (3.3 mg ml_1, 8 mM) was
studied in order to test whether PMA stimulated
hyaluronan secretion through kinase activation. The
selected BIM concentration was above that which causes
100 % inhibition of PMA-induced protein phosphory-
lation in cultured Swiss 3T3 fibroblasts (5 mM, Toullec et
al. 1991). BIM completely abolished the stimulation of
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Figure 1. Stimulation of hyaluronan secretion into the
cavity of the rabbit knee by phorbol-12-myristate-13-
acetate (PMA)
Upper panel, paired experiments in which joint 1 received control
injections of vehicle and joint 2 of the same animal received PMA at
200 ng ml_1 in vehicle (P = 0.002, paired t test). Lower panel,
pooled results and mean (horizontal line) from 26 control joints
and 14 PMA-treated joints. The secretion rate was significantly
raised by PMA (P < 0.0001, Mann-Whitney U test).
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hyaluronan secretion by PMA (Fig. 3). In nine joints
treated with both PMA and BIM the mean hyaluronan
secretion rate, 3.16 ± 0.56 mg h_1, was one-third of that
evoked by the PMA alone (P < 0.001, Newman-Keuls
multiple comparison test). The secretion rate in the
presence of PMA and BIM was not significantly different
from the basal secretion rate of 4.4 ± 0.4 mg h_1 (P > 0.05,
Newman-Keuls multiple comparison test), which leads to
the inference that most of the basal hyaluronan secretion is
not dependent on a basal level of PKC activity. This issue
was subsequently tested directly (see below).
The above PMA + BIM experiments were unpaired
because early paired experiments, in which PMA + BIM
were injected into one knee and PMA alone into the
contralateral knee, indicated that sufficient BIM is
absorbed into the circulation in vivo to inhibit the
contralateral joint (Fig. 3, right column). In seven animals
treated with 200 ng ml_1 PMA in one joint and
PMA + BIM in the contralateral joint, the hyaluronan
secretion rate in the PMA-alone joint was 3.9 ± 0.6 mg h_1
(n = 7 ‘cross-circulation’ joints), compared with
10.1 ± 1.2 mg h_1 (n = 14) in joints injected with
200 ng ml_1 PMA in the absence of circulating BIM
(P < 0.001, Mann-Whitney U test). The IC50 of BIM is
~0.01 mM in vitro (Toullec et al. 1991), and a calculation
based on the intra-articular half-life and replacement
protocol indicates that whole-body extracellular fluid
concentration in a 3 kg rabbit should reach 0.01 mM within
the first hour, neglecting renal excretion.
Effect of CX on PMA-stimulated hyaluronan
secretion
To test whether the stimulatory effect of PKC on
hyaluronan secretion is mediated by the induction of new
protein synthesis, the ribosome translation inhibitor CX
(100 mg ml_1, 0.36 mM) was infused with PMA
(200 ng ml_1) into eight joints. The concentration of CX
exceeded that which completely inhibits protein synthesis
in cultured chondrocytes (Bansal & Mason, 1986),
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Figure 2. Dose–response relation for
effect of PMA on hyaluronan secretion
into joints (means ± S.E.M.)
Basal secretion rate of hyaluronan in the
absence of PMA is plotted at 0.1 ng ml_1 on the
logarithmic scale.
Figure 3. Inhibition of PMA-induced
hyaluronan secretion by
bisindolylmaleimide (BIM, 3.3 µg ml_1)
The infused PMA concentration was zero for the
left column (basal rate) and 200 ng ml_1 for the
other 3 columns. The column labelled ‘cross-
circulation’ shows the secretion rate in joints that
received PMA while the contralateral joint
simultaneously received PMA + BIM; the low
secretion rate in the PMA-stimulated joints is
attributed to circulating BIM. Means ± S.E.M.;
*** P < 0.001, Newman-Keuls test comparison
with PMA; differences between columns 1, 3 and 4
were not significant.
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fibroblasts (Smith et al. 1995) and smooth muscle (Bartlett
et al. 1999) but is not cytotoxic (Mapleson & Buchwald,
1981). CX substantially reduced the stimulatory effect of
PMA on hyaluronan secretion, though not to the same
degree as BIM; the hyaluronan secretion rate remained
above the basal level. In four paired experiments where
one joint received PMA and the other PMA + CX, CX
reduced the secretion rate in every case, from
13.0 ± 3.8 mg h_1 in the presence of PMA to 8.1 ± 3.3mg h_1 in the presence of PMA + CX (P = 0.04, paired t
test) (Fig. 4, upper panel). In a total of eight joints treated
with PMA + CX the hyaluronan secretion rate,
5.8 ± 1.7 mg h_1, was substantially reduced compared with
that evoked by PMA alone, 10.1 ± 1.2 mg h_1 (n = 14,
200 ng ml_1 PMA; P < 0.01, Newman-Keuls test) (Fig. 4,
lower panel). Although the residual secretion rate was
higher than the basal secretion rate (4.4 ± 0.4 mg h_1,
n = 26) or the PMA + BIM secretion rate (3.2 ± 0.6 mg h_1,
n = 9), the difference did not reach statistical significance
(P > 0.05, Newman-Keuls test).
Effects of BIM and CX on basal secretion rate
To assess the contributions of basal PKC activity and
protein turnover to basal hyaluronan secretion in vivo, 10
joints were treated with BIM alone (3.3 mg ml_1) and eight
joints with CX alone (100 mg ml_1). No PMA was present
in either joint in these experiments.
In non-stimulated joints treated with BIM a substantial
hyaluronan secretion persisted, namely 3.07 ± 0.61 mg h_1
(n = 10) (Fig. 5). The secretion rate was 29 % lower,
however, than the basal rate (4.35 ± 0.37 mg h_1, n = 26)
(P = 0.03, Mann-Whitney U test). Similarly, the secretion
rate of 3.11 ± 0.40 mg h_1 for all the BIM-inhibited joints,
pooling both the BIM-alone and PMA + BIM-treated
joints (n = 19), was significantly lower than the basal
secretion rate (P = 0.02, Mann-Whitney test).
CX treatment had no detectable effect on basal hyaluronan
secretion rate over 6 h (Fig. 5). The mean secretion rate in
CHX-treated joints, 4.20 ± 0.67 mg h_1 (n = 8), was only
slightly less than the mean basal rate of 4.35 ± 0.37 mg h_1
(P = 0.9, Mann-Whitney test).
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Figure 4. Partial inhibition of PMA-induced hyaluronan
secretion by cycloheximide (CX, 100 µg ml_1)
Top panel, experiments on pairs of joints in same animal (P = 0.04,
paired t test, n = 4 rabbits). Bottom panel, pooled results. The
infused PMA concentration was 200 ng ml_1 except for the left
column (basal rate). Means ± S.E.M.; *** P < 0.001, ** P < 0.01,
Newman-Keuls test comparison with PMA; P > 0.05 for column 1
vs. column 3.
Figure 5. Effects of bisindolylmaleimide (BIM,
3.3 µg ml_1) and CX (100 µg ml_1) on basal, unstimulated
rate of hyaluronan secretion into joint cavity
The boxes show quartiles and medians, and the bars show ranges.
BIM reduced the basal secretion rate (* P = 0.03, Mann-Whitney U
test). CX did not significantly alter basal secretion rate over 6 h.
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Effect of PMA on indices of synovial inflammation
PMA might, in principle, indirectly stimulate hyaluronan
secretion by triggering an inflammatory synovitis. We
tested this in a joint using the inflammation-assay method
of Poli et al. (2001, 2002). First, a 150 ml bolus of
200 ng ml_1 PMA was injected into the joint cavity and the
pressure recorded through a cannula. The rate of pressure
decay after a bolus injection is an index of net trans-
synovial fluid escape. The observed decay over 30 min,
_0.03 cmH2O min
_1, was in the normal range for Ringer
solution (mean _0.05 ± 0.01 cmH2O min
_1, Poli et al.
2001). By contrast intra-articular pressure increases with
time during an inflammatory response, due to increased
synovial capillary filtration. Next, a bolus of Evans blue-
labelled albumin (EVA) was given intravenously and the
joint cavity infused continuously with the PMA solution at
a controlled pressure, which was raised at 15 min intervals
to a final intra-articular volume of ~2 ml (20 cmH2O).
Trans-synovial flow at each pressure was measured as
described by Poli et al. (2002). EVA clearance from plasma
into the joint cavity was measured by cavity washout every
15 min for 2 h. The net EVA clearance rate, 11.1 ml h_1
over 2 h, was at the upper limit of the range for Ringer-
infused joints (mean 6.2 ± 1.4, range 1.5–11.1 ml h_1). This
contrasts with EVA clearances of > 100 ml h_1 after
endothelial barrier breakdown (Poli et al. 2002). The
hydraulic conductance of the PMA-treated synovium,
calculated as trans-synovial flow per unit increase in joint
pressure, was 0.65 ± 0.09 ml min_1 cmH2O_1, similar to the
mean for Ringer solution (0.87 ± 0.22 ml min_1 cmH2O_1)
cf. 1.86 ± 0.11 ml min_1 cmH2O_1 after barrier breakdown
(Poli et al. 2002). There was thus no evidence of an acute
inflammatory response to intra-articular PMA.
Effect of vehicle DMSO and ethanol on hyaluronan
secretion
We tested whether 0.01–0.10 % DMSO–ethanol solution,
the solvent concentrations in 200–2000 ng ml_1 PMA
solutions, stimulated hyaluronan secretion. The mean
hyaluronan secretion rate in joints receiving 0.01 %
DMSO–ethanol in Ringer solution, 3.4 ± 0.6 mg h_1
(n = 8), was not significantly different from that in 14
joints receiving plain Ringer solution, namely
4.7 ± 0.7 mg h_1 (n = 14; P = 0.20, Mann-Whitney test). In
a single joint treated with 0.1 % DMSO–ethanol in Ringer
solution the hyaluronan secretion rate, 2.2 mg h_1, was
within the Ringer control range (1.6–8.5 mg h_1). The
results showed that the stimulation of hyaluronan
synthesis by PMA-containing solutions is not caused by the
traces of organic solvent in the vehicle. Similarly, Suzuki et
al. (1995) found that DMSO at 0.02–0.20 % has little effect
on hyaluronan secretion by cultured human fibroblasts;
0.50 % DMSO has no detectable effect on synovial
permeability (Poli et al. 2002); and DMSO at 0.50 % is not
toxic to hippocampal cells (Doerner et al. 1990).
DISCUSSION
The principle new findings were that PMA stimulates the
secretion of hyaluronan into joint fluid up to 5-fold in vivo:
BIM completely blocks the response: CX partially blocks it:
and control hyaluronan secretion rate is reduced by BIM
but not CX over 6 h.
Methodological issues
The administration of a 1 ml intra-articular loading dose,
to distribute the drug throughout the joint cavity, distends
the cavity initially to ~6 cmH2O. This may in principle
cause a moderate stimulation of the control hyaluronan
secretion rate above true basal level. The basal rate in non-
distended joints was 4.8 + 0.8 mg h_1 in a previous study,
and the rate in volume-expanded joints (2 ml) was
5.8 ± 0.8 mg h_1 (Coleman et al. 1997). A comparison of
these results with the present control rate, 4.4 ± 0.4 mg h_1,
provides no evidence for an increase above basal rate in the
controls. Comparisons within the present study were
always between joints receiving identical volumes of
injectate.
Effect of PMA on hyaluronan secretion
The demonstration of PMA-induced hyaluronan
secretion into joints extends previous work in vitro to an
intact organ system in vivo. PMA stimulates hyaluronan
secretion between 2- and 10-fold in cultured B6, testicular
peritubular, glioma and mesothelial cell lines over 6 h
(Heldin et al. 1992; Klewes & Prehm, 1994; Asplund et al.
1998; Thiébot et al. 1999). Since hyaluronan is not stored
in vesicles and the total quantity of pre-existing
hyaluronan in rabbit synovium is only 6–11 mg (Price et al.
1996; Levick et al. 1999), the PMA-stimulated secretion
rates must reflect increased net hyaluronan synthase
(HAS) activity.
PMA activates both the conventional and novel isoforms
of PKC, including the a, d and e isoforms recently
demonstrated in rabbit synoviocytes (Momberger et al.
2003). BIM blocks the catalytic domain of PKC a, b, d ande. The complete inhibition of PMA-induced hyaluronan
secretion by BIM supports the view that activated PKC
mediates the response. BIM is highly selective for PKC,
with a 200-fold greater affinity for PKC over PKA (Toullec
et al. 1991). The latter group showed that 5 mM BIM (their
highest concentration) had no effect on protein kinase A-
dependent phosphorylation in cultured fibroblasts.
CX-suppressible component of stimulated response
Since CX inhibited 75 % of the response to PMA, it appears
that PKC acts in part by inducing the synthesis of new
protein(s) – either HAS itself or a regulatory protein. By
contrast, Suzuki et al. (1995) observed little effect of CX on
PMA-stimulated hyaluronan secretion in fibroblasts in
vitro. Other groups, however, report that CX almost totally
abrogates the HAS activity increase in cultured mesothelial
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cells, B6 cells and orbital fibroblasts stimulated
respectively by platelet-derived growth factor, fetal calf
serum and leukoregulin (Heldin et al. 1992; Klewes &
Prehm, 1994; Smith et al. 1995), implicating gene
transcription and protein synthesis de novo.
PKC can induce gene transcription through activation of
the ERK-kinase cascade, which activates the gene
regulatory protein Elk-1; and through phosphorylation of
Ik-B leading to the release of the gene regulatory protein
NF-kB. PKC may upregulate HAS2, since HAS2
transcription is upregulated by growth factors that activate
PKC (Feusi et al. 1999; Pienimäki et al. 2001).
Alternatively, regulatory proteins or precursor enzymes
such as uridine diphosphoglucose dehydrogenase (UDP)
could be upregulated, as happens during joint cavitation
(Ward et al. 1999). It seems unlikely, however, that
precursor supply is rate-limiting, because supplementary
UDP-glucose and glucosamine do not enhance
hyaluronan synthesis in vitro (Sisson et al. 1980). A further
possibility is that HAS mRNA translation rather than
transcription might be enhanced, since the translation
initiation factor e1F-4E is activated by PMA-induced
phosphorylation in cardiac myocytes (Wada et al. 1996).
CX-resistant component of stimulation
About 25 % of the PMA-stimulated hyaluronan secretion
was not inhibited by CX at a concentration that completely
blocks protein synthesis (Bansal & Mason, 1986; Smith,
Wang & Evans, 1995; Bartlett, Sawdy & Mann, 1999). This
finding, like the work of Klewes & Prehm (1994) and
Suzuki et al. (1995) in vitro, indicates that part of the
stimulatory effect of PKC is unrelated to new protein
synthesis. The residual stimulation has been attributed to
serine phosphorylation of pre-existing HAS or associated
34 kDa, 52 kDa and larger protein co-factors. In support,
alkaline phosphatase treatment of plasma membranes
from stimulated cell lines reduces the synthase activity by
50 % (Klewes & Prehm, 1994). The intracellular domain of
HAS2 possesses consensus sequences for phosphorylation
by PKC, protein kinase A (PKA) and tyrosine kinase, but a
specific regulatory domain has not been identified (Ohno
et al. 2001). Our results in joints are compatible with both
increased gene transcription/translation and the
phosphorylation of pre-existing protein as mechanisms of
increased hyaluronan synthase activity in vivo.
If the HAS half-life were short, CX-resistant stimulation
could be brought about, in principle, by reduced HAS
degradation. This cannot apply, however, if HAS activity
terminates upon synthesis of a single hyaluronan chain
(Kitchen & Cysyk, 1995). Nor can it apply if the half-life of
synovial HAS in vivo is > 6 h, as seems to be the case (see
below). For the same reason HAS mRNA stabilisation is
unlikely to be the regulatory mechanism.
Interactions amongst kinases
Activated PKCa commonly translocates to a particulate
fraction to trigger the extracellular signal-regulated kinase
(ERK) cascade (Kanashiro & Khalil, 1998), which in turn
activates nuclear transcription factors (Schönwasser et al.
1998). In keeping with this, PKCa translocation and
ERK1/2 phosphorylation have been observed in stretched,
hyaluronan-secreting rabbit synoviocytes (Momberger et
al. 2003). Likewise, phospho-ERK1 and hyaluronan
appear in the joint line at the time of joint cavitation
during embryogenesis (Ward et al. 1999).
It is possible that PKC might act partly through PKA
activation. The action of PKC on Gi protein can enhance
adenylate cyclase production of cAMP and hence PKA
activity (Kanashiro & Khalil, 1998). cAMP-PKA activation
stimulates hyaluronan synthesis in vitro (Sisson et al. 1980;
Klewes & Prehm, 1994; Suzuki et al. 1995). Although PKC
rather than PKA is the main regulator of HAS activity in
fibroblasts in vitro (Suzuki et al. 1995), this aspect has not
yet been investigated for synovium in vivo.
Stability of hyaluronan synthase in vivo cf. in vitro
Basal hyaluronan secretion into joints was unaffected by
CX treatment over 6 h (Fig. 5), even though this
concentration of CX was demonstrably active (Fig. 4).
Basal hyaluronan secretion is not dependent, therefore, on
the synthesis of HAS de novo over 6 h. It follows that the
half-life of HAS is more than 6 h in synovium in vivo. This
contrasts with the short half-life of HAS in chondrocytes
and fibroblasts in vitro, namely 100–180 min (Bansal &
Mason, 1986; Kitchen & Cysyk, 1995), and with the
finding that CX reduces basal HAS activity by 50–65 %
over 2–3 h in cultured mesothelial cells and 3T3 fibroblasts
(Heldin et al. 1992; Kitchen & Cysyk, 1995). In
subcultured skin and synovial fibroblasts the effect of CX on
basal hyaluronan synthesis ranges from total suppression
over 24 h through partial suppression to no effect at all
(Smith & Hamerman, 1968; Sisson et al. 1980; Mapleson &
Buchwald, 1981). The present results indicate that HAS
stability is much greater in synoviocytes in situ than in most
cultured cell lines. This in turn raises the issue of whether
phenotypic, metabolic changes may occur in mesenchymal,
integrin-bound cells removed from the influence of their
normal, highly complex interstitial environment.
Does basal synovial hyaluronan secretion depend on
basal PKC activity?
On this question too, the synovial results in vivo differ
from those on cells in vitro. PKC inhibition greatly reduces
basal hyaluronan synthesis by quiescent cultured
fibroblasts (Suzuki et al. 1995) whereas it reduces basal
hyaluronan synthesis by synovium in vivo by only 29 %.
We conclude that ~29 % of the basal hyaluronan secretion
into joints is driven by a basal level of PKC activity and the
majority of the basal secretion, ~71 %, is not dependent on
classical/novel PKC isoform activity.
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Physiological and clinical significance of results
Hyaluronan must be secreted continuously into the joint
fluid in order to maintain an effective concentration in the
face of fluid turnover. Fluid turnover is brought about by
synovial capillary filtration into the cavity and lymphatic
clearance of fluid escaping from it. A high hyaluronan
concentration is needed to prevent the synovial fluid from
seeping too rapidly out of the joint cavity. A high
hyaluronan concentration is also necessary for
hydrodynamic lubrication during high frequency, low-
load movements, because this form of lubrication depends
on synovial fluid viscosity, which is hugely increased by
hyaluronan. If hyaluronan secretion rate were fixed and
unregulated, any increase in capillary filtration into the
joint cavity would threaten viscous lubrication by diluting
the hyaluronan. Distension of the cavity, however, by
increased intra-articular fluid volume, stretches the
synoviocytes (McDonald & Levick, 1988) and stimulates
hyaluronan secretion (Coleman et al. 1997). This
constitutes a homeostatic mechanism tending to maintain
the intra-articular hyaluronan concentration. The
demonstration that PKC activation powerfully stimulates
intra-articular hyaluronan secretion provides a potential
insight into the transduction pathway in vivo and is a sine
qua non for our working hypothesis, namely that synovial
PKC activation is part of a mechanotransduction pathway
that links joint stretch to hyaluronan secretion.
Recent work on stretched synoviocytes in vitro supports
the above hypothesis by showing that stretch activates
PKCa and increases hyaluronan secretion (Momberger et
al. 2003). Mechanical deformation of a cell is known to
stress the integrin–matrix linkages at focal adhesion sites,
where PKCa is concentrated (Kanashiro & Khalil, 1998;
Mellor & Parker, 1998). This activates the ERK cascade,
probably through the focal adhesion kinase–phospho-
lipase C-g1–DAG–PKC pathway (Schmidt et al.1998;
MacKenna et al. 1998; Karim, 1998; Zhang et al. 1999).
Synovial PKC activation is also likely to be involved in the
stimulation of hyaluronan secretion into joints with
inflammatory arthritis. In these conditions the joint cavity
is distended by a cytokine-rich effusion and contains a
greatly increased mass of hyaluronan. Pro-inflammatory
mediators in the effusion, such as interleukin b1 and
tumour growth factor b, stimulate hyaluronan synthesis
through the activation of PKC (Heldin et al. 1992; Ito et al.
1993; Haubeck et al. 1995; Suzuki et al. 1995; Kolomytkin
et al. 1999; Tanimoto et al. 2001). PKC activation is also
reported to inhibit the progression of osteoarthritis in
rabbit knees (Hamanishi et al. 1996).
In conclusion, the study showed that PKC is part of a
transduction cascade that regulates hyaluronan secretion
into intact synovial joints in vivo. The study also revealed
substantial differences between organ-specific hyaluronan
secretion in vivo and hyaluronan secretion by cell lines in
vitro, which may reflect the physiological importance of
cellular environment and matrix binding in determining
metabolic function. Further work is needed to determine
which proteins are upregulated by PKC and how the
activity of pre-existing HAS is regulated.
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